07/07/2015 07:08:35 Free Membership Login

Bristol Myers Sqibb News (NYSE:BMY)

DateTimeSource
Headline
06/26/20158:30AMPRNUSAlexandria Real Estate Equities, Inc. Announces 15-Year Anchor Lease of 208,000 RSF with Bristol-Myers Squibb at 100 Binney S...
Alexandria Real Estate Equities, Inc. Announces 15-Year Anchor Lease of 208,000 RSF with Bristol-Myers Squibb at 100 Binney Street at the Alexandria Center® at Kendall Square in Cambridge, MA PR Newswire PASADENA, Calif., June 26, 2015 PASADENA, Calif., June 26, 2015 /PRNewswire/ -- Alexandria Real Estate Equities, Inc... More...>>
06/25/201512:29PMDJNBristol-Myers to Close Sites, Cut 100 Jobs -- Update
By Cassandra Jaramillo Bristol-Myers Squibb Co. said Thursday it plans to close two sites, eliminate 100 positions and discontinue discovery-research efforts in virology while it makes adjustments for other expansions in research and development. Bristol said it plans to close its Waltham, Mass., and Wallingford, Conn... More...>>
06/25/201511:50AMDJNBristol-Myers to Close Sites, Cut 100 Jobs
Bristol-Myers Squibb Co. said Thursday it plans to close two sites, eliminate 100 positions and discontinue discovery-research efforts in virology while it makes adjustments for other expansions in research and development. Bristol said it plans to close its Waltham, Mass., and Wallingford, Conn., sites and open a new... More...>>
06/25/201511:40AMDJNBristol-Myers to Close Sites, Cut 100 Jobs
By Cassandra Jaramillo Bristol-Myers Squibb Co. said Thursday it plans to close two sites, eliminate 100 positions and discontinue discovery-research efforts in virology while it makes adjustments for other expansions in research and development. Bristol said it plans to close its Waltham, Mass., and Wallingford, Conn... More...>>
06/25/20159:30AMBWBristol-Myers Squibb Expands R&D Presence Within Hubs of World Class Science and Innovation
Bristol-Myers Squibb Company (NYSE:BMY) today announced important next steps in the evolution of the company’s R&D organization, including plans to expand its presence within hubs of scientific excellence and innovation with the opening of a new state-of-the-art research site in Cambridge, Mass. in addition to the... More...>>
06/22/20153:12AMDJNAllied Minds: Allied-Bristol Life Sciences Licenses IP from Harvard
LONDON--Allied Minds PLC (ALM.LN) said Monday that Allied-Bristol Life Sciences, has entered into a licensing agreement with Harvard University based on research and intellectual property developed in Professor Whitman's lab at the Harvard School of Dental Medicine. The licensing agreement with Harvard's Office of Technology... More...>>
06/22/20152:00AMBWAllied-Bristol Life Sciences Licenses Intellectual Property from Harvard University
Allied-Bristol Life Sciences (ABLS) has licensed intellectual property developed in Professor Malcolm Whitman’s laboratory at Harvard. The intellectual property includes lead molecules and a differentiated mechanism to develop drugs for treating chronic fibrotic and autoimmune diseases. Allied-Bristol Life Sciences... More...>>
06/21/201511:06AMTMFWhat Is Cancer Immunotherapy?
http://www.fool.com/investing/general/2015/06/21/what-is-immunotherapy.aspx?source=eptadnlnk0000002 More...>>
06/19/201511:37AMBWEuropean Commission Approves Bristol-Myers Squibb’s Opdivo (nivolumab), the First & Only PD-1 Checkpoint Inhibitor Approved...
Approval follows accelerated assessment by Committee for Medicinal Products for Human Use, marking a rapid pace in bringing a new option for patients with advanced melanoma Approval based on CheckMate -066 trial demonstrating superior overall survival vs. dacarbazine in the first-line setting and CheckMate -037 trial showing... More...>>
06/19/20157:58AMTMFWhy Bristol-Myers Squibb Co.'s Stock Could Sink
http://www.fool.com/investing/general/2015/06/19/why-bristol-myers-squibb-cos-stock-could-sink.aspx?source=eptadnlnk0000002 More...>>
06/18/20159:00AMBWBristol-Myers Squibb to Announce Results for Second Quarter 2015 on July 23
Bristol-Myers Squibb Company (NYSE:BMY) will announce results for the second quarter of 2015 on Thursday, July 23, 2015. During a conference call at 10:30 a.m. EDT on July 23, company executives will review financial information and will address inquiries from investors and analysts. Investors and the general public are... More...>>
06/13/20151:16PMTMFWhy I'm Shorting Biotech
http://www.fool.com/investing/general/2015/06/13/why-im-shorting-biotech.aspx?source=eptadnlnk0000002 More...>>
06/11/20152:38AMBWPeptiDream Announces Milestone in Macrocyclic Peptide Drug Discovery Alliance with Bristol-Myers Squibb
PeptiDream Inc., a Tokyo-based biopharmaceutical company (“PeptiDream”)(TOKYO:4587) announced today the achievement of a milestone in one of the discovery programs in its alliance with US-based Bristol-Myers Squibb (NYSE:BMY). The milestone is the decision by Bristol-Myers Squibb to designate a Collaboration Compound... More...>>
06/11/201512:00AMBWBristol-Myers Squibb Demonstrates Commitment to Hematology & Advancing Research & Development Across Multiple Blood Cancers T...
Results from two trials (ELOQUENT-2 & 009) in which elotuzumab’s novel mechanism of action demonstrated a significant and sustained reduction in the risk of disease progression or death in patients with relapsed or refractory multiple myeloma to be presented Updated data from Opdivo (nivolumab) early-stage research... More...>>
06/10/201510:05AMTMFCancer Stocks: 2 to Sell, 1 to Buy
http://www.fool.com/investing/general/2015/06/10/cancer-stocks-2-to-sell-1-to-buy.aspx?source=eptadnlnk0000002 More...>>
06/10/201510:05AMTMFCancer Stocks: 2 to Sell, 1 to Buy
http://www.fool.com/investing/general/2015/06/10/cancer-stocks-2-to-sell-1-to-buy.aspx?source=eptadnlnk0000002 More...>>
06/09/20156:02PMBWNew Post Hoc Analyses of Phase 3b Data Examine Treatment with Orencia (abatacept) Plus Methotrexate (MTX) in Patients with Ea...
AVERT trial data suggests potentially faster onset of clinical response and greater drug-free clinical remission with earlier use in patients taking Orencia plus methotrexate over patients taking methotrexate alone Exploratory data of patients with high ACPA levels at baseline in the AMPLE trial suggest better response... More...>>
06/09/20151:35AMDJNSeattle Genetics, Unum Therapeutics to Develop Cancer Immunotherapy
By Chelsey Dulaney Seattle Genetics Inc. (SGEN) is partnering with startup Unum Therapeutics to develop and commercialize an immunotherapy drug that could potentially be used to treat a wide range of cancers. The partnership will pair Seattle Genetics' antibodies with Unum's novel therapy that uses a patient's T-cells... More...>>
06/08/20157:24AMTMF3 Big Pharma Dividend Stocks That Are Dragging Down Your Returns
http://www.fool.com/investing/general/2015/06/08/3-big-pharma-dividend-stocks-that-are-dragging-dow.aspx?source=eptadnlnk0000002 More...>>
06/07/20151:06PMTMFCancer Drugs: 2 Stocks to Watch
http://www.fool.com/investing/general/2015/06/07/cancer-drugs-2-stocks-to-watch.aspx?source=eptadnlnk0000002 More...>>


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE and AMEX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

1 site:2 us nyse bmy150707 07:08